Feature | May 19, 2014

Pacemaker, Defibrillator Patients Adhering to Remote Monitoring Saw More Than Double Survival Rate

Data presented during at Heart Rhythm 2014 is industry’s largest study of remote management of pacemaker patients

May 19, 2014 — St. Jude Medical announced that data presented during a late-breaking clinical trial session at the 2014 annual scientific sessions of the Heart Rhythm Society (HRS) found an association between adherence to remote monitoring with the Merlin remote monitoring system and a reduction in patient mortality. Results from more than 260,000 patients implanted with either pacemakers or defibrillators demonstrated that patients with high adherence to remote monitoring had more than twice (2.4x) the probability of survival than that of patients without remote monitoring.

The prospective, observational study of U.S. patients also found that the greater the adherence to remote monitoring, the better the patient fared. Patients with high adherence to remote monitoring — measured as weekly transmission of patient data from the [email protected] System to the Merlin.net patient care network at least 75 percent of the time — overall had a 58 percent reduced likelihood of mortality than patients not using remote monitoring and a 35 percent reduced likelihood of mortality than patients with low remote monitoring. Though there was geographic variability, socioeconomic factors were not associated with remote monitoring use.

“This study is the first of its kind to find increased survival when remote monitoring is utilized in pacemaker patients,” said Suneet Mittal, M.D., director of EP at the Valley Hospital Health System of N.Y. and N.J. “Furthermore, our data suggest that, irrespective of whether a patient has a pacemaker or defibrillator, higher use of remote monitoring is associated with better survival. Although these associations require further investigation, these important observations should have significant implications for individual patient care and best-practice guidelines.”

All St. Jude Medical U.S. Food and Drug Administration (FDA) approved implantable cardiac devices capable of radiofrequency (RF) remote monitoring were included in the study, which had a cohort of 262,564. This is the largest study to date of remote monitoring pacemaker patients, and one of the largest for remote monitoring overall.

“Patients with implanted cardiac devices are typically required to visit doctors’ offices several times per year to have their device performance checked, which for many can be impractical. This new research demonstrates that the Merlin patient care system not only adds convenience for physicians and patients, it helps patients to live longer,” said Mark D. Carlson, M.D., chief medical officer for St. Jude Medical.

For more information: www.sjm.com

Related Content

Acutus Medical, AcQMap EP Imaging and Mapping System, CE Mark
News | EP Mapping and Imaging Systems| May 04, 2016
Acutus Medical announced CE Mark approval for its AcQMap High Resolution Imaging and Mapping System and AcQMap Catheter...
Biotronik, FDA, MR Conditional CRT devices, Iperia HF-T, defibrillator, ProMRI
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 03, 2016
Biotronik announced U.S. Food and Drug Administration (FDA) approval of Iperia ProMRI HF-T, a cardiac resynchronization...
CardioMEMS, implantable hemodynamic monitor, Fontan anatomy, Nationwide Children's Hospital, Wexner Medical Center
News | Implantable Cardiac Monitor (ICM)| May 02, 2016
In a recent case series, clinicians from The Heart Center at Nationwide Children’s Hospital and The Ohio State...
radiation dose in the cath lab
News | Radiation Dose Management| May 02, 2016
May 2, 2016 — Starting at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 annual meeting May
AtriCure, AtriClip PRO2 LAA Exclusion System, left atrial appendage, FDA clearance
Technology | Left Atrial Appendage (LAA) Occluders| April 29, 2016
April 29, 2016 — AtriCure Inc. announced U.S.
microtubules, heartbeat mechanics, Perelman School of Medicine study

Microtubules in a cardiomyocyte at rest (top) and when compressed. Image courtesy of the lab of Ben Prosser, Ph.D., Perelman School of Medicine, University of Pennsylvania

News | EP Lab| April 29, 2016
Using new high-resolution microscopy, researchers have found that molecular struts called microtubules (MT) interact...
Boston Scientific, FDA, ImageReady MR-Conditional Pacing System
Technology | EP Lab| April 28, 2016
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for a suite of products deemed safe for...
breast cancer, herceptin chemotherapy drug, heart damage, monitoring, Journal of Clinical Oncology study
News | Cardiac Diagnostics| April 28, 2016
April 28, 2016 — Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored
Feature | Business| April 28, 2016 | Dave Fornell
 
coronary CT angiography, CCTA, SCOT-HEART trial substudy, SCCT
News | Computed Tomography (CT)| April 26, 2016
The results of a secondary analysis of the SCOT-HEART trial show that coronary computed tomography angiography (CCTA)...
Overlay Init